Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.34 |
| ▸ | SELE | P16581 | 1/20 | 0.34 |
| ▸ | TRPM8 | Q7Z2W7 | 3/20 | 0.33 |
| ▸ | RAB9A | P51151 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | BCKDK | O14874 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12490263 | 0.72 | CYP2A6 (0.41) | CYP2A6TRPM8PTPN2 | |
| SCHEMBL793711 | 0.71 | CYP2A6 (0.58) | CYP2A6RAB9AMEN1KMT2APTPN2 | |
| SCHEMBL6957547 | 0.71 | CYP2A6 (0.58) | CYP2A6RAB9AMEN1ALDH1A1MAPT | |
| SCHEMBL15111011 | 0.67 | — | — | |
| SCHEMBL16279435 | 0.64 | CYP2A6 (0.46) | CYP2A6PTPN2 | |
| SCHEMBL1848139 | 0.63 | CYP2A6 (0.33) | CYP2A6PKMPTPN2 | |
| SCHEMBL1850221 | 0.63 | CYP2A6 (0.33) | CYP2A6PKM | |
| SCHEMBL31750792 | 0.63 | CYP2A6 (0.41) | CYP2A6ICAM1SELEALDH1A1SMN1; SMN2 | |
| SCHEMBL96131 | 0.63 | CES2 (0.37) | ALDH1A1 | |
| SCHEMBL27293788 | 0.63 | CYP2A6 (0.53) | CYP2A6ICAM1SELEMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9540360-B2 | Sulfonamide compounds having TRPM8 antagonistic activity | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-01-10 | — | — | US | disclosed |
| US-9540360-B2 | Sulfonamide compounds having TRPM8 antagonistic activity | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-01-10 | — | — | US | disclosed |
| US-9540360-B2 | Sulfonamide compounds having TRPM8 antagonistic activity | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-01-10 | — | — | US | disclosed |
| EP-2686302-B1 | SULFONAMIDE COMPOUNDS HAVING TRPM8 ANTAGONISTIC ACTIVITY | MITSUBISHI TANABE PHARMA CORP (JP) | 2016-08-10 | — | — | EP | disclosed |
| EP-2686302-B1 | SULFONAMIDE COMPOUNDS HAVING TRPM8 ANTAGONISTIC ACTIVITY | MITSUBISHI TANABE PHARMA CORP (JP) | 2016-08-10 | — | — | EP | disclosed |
| US-20150218143-A1 | SULFONAMIDE COMPOUNDS HAVING TRPM8 ANTAGONISTIC ACTIVITY | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-08-06 | — | — | US | disclosed |
| US-20150218143-A1 | SULFONAMIDE COMPOUNDS HAVING TRPM8 ANTAGONISTIC ACTIVITY | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-08-06 | — | — | US | disclosed |
| US-20150218143-A1 | SULFONAMIDE COMPOUNDS HAVING TRPM8 ANTAGONISTIC ACTIVITY | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-08-06 | — | — | US | disclosed |
| US-8987445-B2 | Sulfonamide compounds having TRPM8 antagonistic activity | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-03-24 | — | — | US | disclosed |
| US-8987445-B2 | Sulfonamide compounds having TRPM8 antagonistic activity | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-03-24 | — | — | US | disclosed |
| US-8987445-B2 | Sulfonamide compounds having TRPM8 antagonistic activity | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-03-24 | — | — | US | disclosed |
| EP-2686302-A1 | SULFONAMIDE COMPOUNDS HAVING TRPM8 ANTAGONISTIC ACTIVITY | Mitsubishi Tanabe Pharma Corporation (JP) | 2014-01-22 | — | — | EP | disclosed |
| US-20140005393-A1 | SULFONAMIDE COMPOUNDS HAVING TRPM8 ANTAGONISTIC ACTIVITY | KALLYOPE, INC. | 2014-01-02 | — | — | US | disclosed |
| WO-2012124825-A1 | SULFONAMIDE COMPOUNDS HAVING TRPM8 ANTAGONISTIC ACTIVITY | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-09-20 | — | — | WO | disclosed |
| WO-2012124825-A1 | SULFONAMIDE COMPOUNDS HAVING TRPM8 ANTAGONISTIC ACTIVITY | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150218143-A1 | SULFONAMIDE COMPOUNDS HAVING TRPM8 ANTAGONISTIC ACTIVITY | TRPM8, TRPM7, TRPM2 | CYP2A6 1496/4885ICAM1 4205/4885SELE 3346/4885 |
| US-20140005393-A1 | SULFONAMIDE COMPOUNDS HAVING TRPM8 ANTAGONISTIC ACTIVITY | TRPM8, TRPM7, TRPM2 | CYP2A6 1450/4885ICAM1 4037/4885SELE 3219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.